Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
NCT04322318Phase 2Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Oct 2020
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 6
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection, pegylated liposomal doxorubicin, cyclophosphamide, carboplatin, etoposide and 3 more in Wilms' tumor (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free survival at 5 years. Started Oct 2020; status: recruiting.
02
Drugs
vincristine sulfate liposome injectionpegylated liposomal doxorubicincyclophosphamidecarboplatinetoposide
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on NCT04322318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322318.